Tango Therapeutics (TNGX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
17 Apr, 2026Voting matters and shareholder proposals
Election of three Class II directors: Malte Peters, M.D., Kanishka Pothula, and Mace Rothenberg, M.D., with board recommendation to vote for all nominees.
Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote to approve compensation of named executive officers, with board recommendation to vote for.
Board may consider other business that arises at the meeting or any adjournment.
Board of directors and corporate governance
Board recommends all director nominees for election to Class II positions.
Executive compensation and say-on-pay
Advisory vote on executive compensation for named executive officers is included as a proposal.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Tango Therapeutics
- Shareholders to vote on directors, auditor, and executive pay amid strong clinical and financial progress.TNGX
Proxy filing17 Apr 2026 - Advancing PRMT5 inhibitors for MTAP-deleted cancers with pivotal trials and strong leadership.TNGX
44th Annual J.P. Morgan Healthcare Conference13 Apr 2026 - Promising PRMT5 inhibitor data and strategic collaborations aim to reshape cancer treatment.TNGX
Leerink Global Healthcare Conference 202613 Mar 2026 - Vopimetostat delivers best-in-class efficacy and safety, driving pivotal trials and pipeline growth.TNGX
Corporate presentation11 Mar 2026 - Vopimetostat trials progress, cash runway extends to 2028, and leadership transitions completed.TNGX
Q4 20255 Mar 2026 - Pivotal trials and combination studies for vopimetostat show strong promise in cancer therapy.TNGX
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Pivotal and combination trial data for vopimetostat, plus pipeline updates, are expected this year.TNGX
Guggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026 - Simultaneous dose expansion of two PRMT5 inhibitors sets up major clinical readouts this year.TNGX
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Second-generation PRMT5 inhibitors advance in competitive trials, with strong funding and pipeline.TNGX
2024 Wells Fargo Healthcare Conference22 Jan 2026